Zheng, Min
Jullien, Denis
Eyerich, Kilian
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Accepted: 2 December 2021
First Online: 21 January 2022
Declarations
:
: This article has been published as part of a journal supplement wholly funded by Boehringer Ingelheim.
: Medical writing support was funded by Boehringer Ingelheim.
: Kilian Eyerich has received consulting fees from AbbVie, Almirall, Bristol Myers Squibb, LEO Pharma, Janssen, Lilly, Novartis, UCB, Pfizer, and Boehringer Ingelheim; grants and/or contracts from AbbVie, LEO Pharma, UCB, and Lilly; and speaking fees from AbbVie, LEO Pharma, Janssen, and Lilly. Kilian Eyerich also declares stock or stock options with Dermagnostix and Dermagnostix R&D. Min Zheng has received consulting fees from AbbVie, Boehringer Ingelheim, Janssen-Cilag, LEO Pharma China, Novartis, Pfizer, and Xian-Janssen. Denis Jullien has received consulting fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Fresenius Kabi, Janssen-Cilag, LEO Pharma, Lilly, MSD, MEDAC, Novartis, Pfizer, UCB, and Sanofi; payment for speakers’ bureaus from AbbVie, Celgene, Janssen-Cilag, LEO Pharma, Lilly, MEDAC, Novartis, and Pfizer; and travel/accommodation expenses reimbursed by AbbVie, Amgen, Biogen, Celgene, Fresenius Kabi, Janssen-Cilag, LEO Pharma, Lilly, MSD, MEDAC, Novartis, Pfizer, UCB, and Sanofi.
: Not applicable.
: Not applicable.
: The sponsor of the supplement and all authors identified and discussed the concept for each chapter and the supplement as a whole; further development of each review article was at the direction of the authors, who provided guidance to OPEN Health Communications on the content of the article, critically revised the work, and approved the content for publication.
: Not applicable.
: Not applicable.
: Not applicable.